What is the recommended treatment for managing asthma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Treatment for Managing Asthma

The cornerstone of asthma management is inhaled corticosteroids (ICS) as first-line controller therapy for persistent asthma, with short-acting beta-agonists (SABA) used as needed for symptom relief. 1, 2

Stepwise Approach to Treatment

Step 1: Mild Intermittent Asthma

  • Use as-needed short-acting beta-agonists (SABA) for symptom relief 3
  • No daily controller medication is needed 1
  • Increasing use of SABA more than twice weekly indicates need for controller therapy 1

Step 2: Mild Persistent Asthma

  • Low-dose inhaled corticosteroids (ICS) are the preferred controller treatment 1, 2
  • Alternative options include leukotriene receptor antagonists or cromoglycate, though these are less effective than ICS 1
  • ICS should be taken daily on a long-term basis to achieve and maintain symptom control 1

Step 3: Moderate Persistent Asthma

  • Low-dose ICS plus long-acting beta-agonists (LABA) is the preferred treatment 1
  • Alternative option: Medium-dose ICS monotherapy 1, 3
  • Important: LABAs should never be used as monotherapy and must always be combined with ICS 1, 4

Step 4: Severe Persistent Asthma

  • Medium to high-dose ICS plus LABA is the preferred treatment 1, 3
  • For patients aged 12 years or older with allergic asthma inadequately controlled on high-dose ICS plus LABA, consider adding omalizumab (anti-IgE therapy) 1

Acute Exacerbation Management

Assessment of Severity

  • Mild exacerbation: Normal speech, pulse <110/min, respiratory rate <25/min, PEF >50% predicted 1, 2
  • Severe exacerbation: Cannot complete sentences, pulse >110/min, respiratory rate >25/min, PEF <50% predicted 1, 2
  • Life-threatening: Silent chest, cyanosis, poor respiratory effort, confusion, exhaustion 2

Treatment of Exacerbations

  • Mild exacerbations: Nebulized SABA (salbutamol 5mg or terbutaline 10mg) 1, 3
  • Moderate to severe exacerbations: Oral systemic corticosteroids (prednisolone 30-60mg), oxygen if available, and nebulized SABA 1
  • Consider hospital admission for life-threatening features, severe features persisting after initial treatment, or PEF <33% after treatment 2

Medication Effectiveness and Considerations

Inhaled Corticosteroids

  • ICS are the most potent and consistently effective long-term control medications for asthma 1, 5
  • They suppress virtually every step of inflammation in asthmatic airways 5, 6
  • The dose-response curve is relatively flat, with minimal additional benefit from high doses in most patients 5, 7
  • Low-dose ICS is sufficient for most patients with mild persistent asthma 7

Beta-Agonists

  • Short-acting beta-agonists are the most effective therapy for rapid reversal of airflow obstruction 1
  • Long-acting beta-agonists should never be used as monotherapy due to increased risk of asthma exacerbations and death 1, 4
  • LABA combined with ICS is more effective than doubling the dose of ICS in moderate persistent asthma 8

Delivery Devices

  • Consider nebulized therapy for young children, elderly patients, or those unable to use handheld inhalers properly 9
  • Spacer devices can improve delivery of medication from metered-dose inhalers 1
  • Check inhaler technique regularly as part of follow-up 2, 3

Self-Management and Monitoring

  • Provide patients with a written action plan with clear instructions for medication adjustment 2, 3
  • Teach patients to distinguish between "relievers" (bronchodilators) and "preventers" (anti-inflammatory medications) 2
  • Monitor peak expiratory flow (PEF) regularly to assess response to treatment 2, 3
  • Consider step-down of therapy when asthma has been stable for at least 3 months 2, 3

Common Pitfalls to Avoid

  • Overreliance on bronchodilators without anti-inflammatory treatment 2, 3
  • Underestimating severity of exacerbations 2
  • Delayed administration of systemic corticosteroids during severe exacerbations 2
  • Using sedatives in acute asthma (contraindicated) 10
  • Failure to provide patients with written action plans for self-management 3

Follow-Up Recommendations

  • Follow-up within 24-48 hours after acute exacerbations 2, 3
  • Regular review of inhaler technique, adherence, and symptom control 2
  • Patients should not be discharged from hospital until symptoms have stabilized with PEF >75% of predicted/personal best 1, 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Asthma Management Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Asthma Management Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Efficacy of inhaled corticosteroids in asthma.

The Journal of allergy and clinical immunology, 1998

Research

Corticosteroids: the mainstay in asthma therapy.

Bioorganic & medicinal chemistry, 2004

Research

Relative efficacy and safety of inhaled corticosteroids in patients with asthma: Systematic review and network meta-analysis.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2020

Research

Inhaled corticosteroid therapy with nebulized beclometasone dipropionate.

Pulmonary pharmacology & therapeutics, 2010

Guideline

Management of Asthmatic Patients with Thrombocytopenia and Elevated CRP

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.